Cargando…
Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity
BACKGROUND: Using data from syndromic surveillance, the New York City Department of Health and Mental Hygiene (DOHMH) identified an increase in the number of emergency department (ED) visits related to synthetic cannabinoids. Syndromic surveillance data were used to target community-level interventi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613244/ https://www.ncbi.nlm.nih.gov/pubmed/31321202 http://dx.doi.org/10.1186/s40621-019-0210-2 |
_version_ | 1783433016211668992 |
---|---|
author | Nolan, Michelle L. Ehntholt, Amy Merrill, Thomas Weiss, Don Lall, Ramona Paone, Denise |
author_facet | Nolan, Michelle L. Ehntholt, Amy Merrill, Thomas Weiss, Don Lall, Ramona Paone, Denise |
author_sort | Nolan, Michelle L. |
collection | PubMed |
description | BACKGROUND: Using data from syndromic surveillance, the New York City Department of Health and Mental Hygiene (DOHMH) identified an increase in the number of emergency department (ED) visits related to synthetic cannabinoids. Syndromic surveillance data were used to target community-level interventions and assess the real-time impact of control measures in reducing synthetic cannabinoid (“K2”)-related morbidity. METHODS: From April 2015 through September 2015, DOHMH implemented 3 separate interventions to reduce K2-related morbidity by limiting the availability of K2 products. Difference-in-difference analyses compared pre- and post-intervention differences in cannabinoid-related ED visit rates between neighborhoods and controls for Interventions A and B. City-wide count data were used to compare K2-related ED visits before and after Intervention C. RESULTS: Syndromic data showed a reduction in K2-related ED visits following the 3 interventions. Respective decreases in rates of synthetic cannabinoid-related ED visits of 33 and 38% were detected at the neighborhood-level due to Interventions A and B, respectively. A decrease of 29% was calculated at the city level following Intervention C. CONCLUSIONS: In addition to identifying emerging public health concerns, syndromic data can provide valuable real-time evidence on the effectiveness of public health interventions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40621-019-0210-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6613244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66132442019-07-18 Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity Nolan, Michelle L. Ehntholt, Amy Merrill, Thomas Weiss, Don Lall, Ramona Paone, Denise Inj Epidemiol Short Report BACKGROUND: Using data from syndromic surveillance, the New York City Department of Health and Mental Hygiene (DOHMH) identified an increase in the number of emergency department (ED) visits related to synthetic cannabinoids. Syndromic surveillance data were used to target community-level interventions and assess the real-time impact of control measures in reducing synthetic cannabinoid (“K2”)-related morbidity. METHODS: From April 2015 through September 2015, DOHMH implemented 3 separate interventions to reduce K2-related morbidity by limiting the availability of K2 products. Difference-in-difference analyses compared pre- and post-intervention differences in cannabinoid-related ED visit rates between neighborhoods and controls for Interventions A and B. City-wide count data were used to compare K2-related ED visits before and after Intervention C. RESULTS: Syndromic data showed a reduction in K2-related ED visits following the 3 interventions. Respective decreases in rates of synthetic cannabinoid-related ED visits of 33 and 38% were detected at the neighborhood-level due to Interventions A and B, respectively. A decrease of 29% was calculated at the city level following Intervention C. CONCLUSIONS: In addition to identifying emerging public health concerns, syndromic data can provide valuable real-time evidence on the effectiveness of public health interventions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40621-019-0210-2) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-08 /pmc/articles/PMC6613244/ /pubmed/31321202 http://dx.doi.org/10.1186/s40621-019-0210-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Short Report Nolan, Michelle L. Ehntholt, Amy Merrill, Thomas Weiss, Don Lall, Ramona Paone, Denise Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity |
title | Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity |
title_full | Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity |
title_fullStr | Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity |
title_full_unstemmed | Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity |
title_short | Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity |
title_sort | novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613244/ https://www.ncbi.nlm.nih.gov/pubmed/31321202 http://dx.doi.org/10.1186/s40621-019-0210-2 |
work_keys_str_mv | AT nolanmichellel noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity AT ehntholtamy noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity AT merrillthomas noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity AT weissdon noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity AT lallramona noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity AT paonedenise noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity |